R-Bridge Healthcare Fund has provided $40 million in synthetic royalty-backed financing to Singapore-based Mirxes. The capital supports the global commercialisation of microRNA (miRNA) technologies for early-stage cancer detection, specifically within the Asia-Pacific region.

• Financing Structure: The $40 million structured transaction utilises a synthetic royalty model with flexible repayment terms to fund market expansion and the development of diagnostic tools for lung, liver, and colorectal cancers.
• Clinical Performance: The company’s lead gastric cancer screening tool demonstrated 87.5% sensitivity for stage 1 cancers and 75% sensitivity for lesions smaller than 1 cm in clinical assessments.
• Market Growth: Proceeds will be used to scale operations and clinical pipeline development across Southeast Asia, China, and Japan, leveraging an existing portfolio of over 90 patents.

This summary is based on a press release issued by CBC Group.